Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.04 USD | -1.18% | +11.01% | -35.30% |
Apr. 09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
Apr. 09 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
Business Summary
Number of employees: 68
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gene Control Medicines
100.0
%
| 15 | 100.0 % | 10 | 100.0 % | -33.23% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 15 | 100.0 % | 10 | 100.0 % | -33.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
David Roth
CTO | Chief Tech/Sci/R&D Officer | 61 | 15-12-06 |
Gerald Quirk
ADM | Chief Administrative Officer | 56 | 16-08-31 |
Karen Hunady
IRC | Investor Relations Contact | - | 22-09-30 |
Lisa Roberts
HRO | Human Resources Officer | - | 11-12-31 |
Kristin Stephens
PRN | Corporate Officer/Principal | 51 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Deborah Dunsire
BRD | Director/Board Member | 61 | 21-09-08 |
Peter Wirth
CHM | Chairman | 73 | 17-01-29 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Richard Young
FOU | Founder | 70 | 11-11-08 |
S. Gail Eckhardt
BRD | Director/Board Member | 66 | 20-09-07 |
Andrew Oh
BRD | Director/Board Member | 53 | 22-09-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,728,337 | 26,442,318 ( 98.93 %) | 0 | 98.93 % |
Company contact information
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive 4th floor
02140-2325, Cambridge
+617 744 1340
http://www.syros.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.30% | 135M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SYRS Stock
- Company Syros Pharmaceuticals, Inc.